Uncategorized
Lessons learned over 5 years of follow-up with Kamra inlay for presbyopia
MILAN — Long-term outcomes with the Kamra small aperture inlay have shown how to ensure safety and optimize efficacy of the implant. At the OSN Italy meeting, Jay Pepose, MD, PhD, said that lessons were learned from the FDA investigational device exemption study, which enrolled 507 patients from 24 sites in the U.S., Europe and Asia-Pacific region. The Kamra inlay (AcuFocus) is implanted monocularly in a corneal pocket in the nondominant eye. The inlay blocks the peripheral unfocused light and allows only focused light to reach the retina.